This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Arkadius Pichota

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOless than a year
Eigendom CEOn/a
Management gemiddelde ambtstermijnless than a year
Gemiddelde ambtstermijn bestuur6.5yrs

Recente managementupdates

Recent updates

MorphoSys: Hold Rating Until The Novartis Deal Closes

May 01

Novartis And MorphoSys Are A Perfect Match

Feb 06

MorphoSys: Positive Pelabresib Data Finally Unlocking Upside

Jan 18

MorphoSys updates Q2 & FY22 guidance below prior provided levels

Jul 26

MorphoSys May Not Recover From Adventurous Constellation Buyout

May 04

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Jan 28

Incyte and MorphoSys presents new three-year data for blood cancer therapy

Jun 04

MorphoSys reports Q1 results

May 05

MorphoSys AG appoints Sangamo 's Sung Lee as new CFO

Jan 06

MorphoSys AG (MOR) Investor Presentation - Slideshow

Dec 08

MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation

Nov 22

MorphoSys reports Q3 results

Nov 11

CEO

Arkadius Pichota

less than a year

Tenure

Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Charlotte Lohmann
Chief Legal and Human Resources Officer & Member of Management Board4.6yrs€1.10m0.0036%
$ 99.7k
Arkadius Pichota
Chief Executive Officerless than a yeargeen gegevensgeen gegevens
Lukas Gilgen
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Tim Demuth
Chief Research & Development Officer1.8yrsgeen gegevensgeen gegevens
Klaus De Wall
Head of Accounting & Taxno datageen gegevensgeen gegevens
Margit Urban
Head of Discovery Alliances & Technologiesno datageen gegevensgeen gegevens
Julia Neugebauer
Head of Investor Relationsno datageen gegevensgeen gegevens
Barbara Krebs-Pohl
Chief Business Officerno datageen gegevensgeen gegevens
Günter Wellnhofer
Head of Technical Operationsno datageen gegevensgeen gegevens
Harald Watzka
Head of Alliance Managementno datageen gegevensgeen gegevens
Yen Ching Chua
Head of Clinical Operationsno datageen gegevensgeen gegevens
Kathrin Tissot
Head of Business Teamno datageen gegevensgeen gegevens

1.0yrs

Gemiddelde duur

Ervaren management: MOR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Bruce Cheson
Member of Scientific Advisory Board7.9yrsgeen gegevensgeen gegevens
Gunther Adolf
Member of Scientific Advisory Board7.9yrsgeen gegevensgeen gegevens
Sergio Quezada
Member of Scientific Advisory Board7.9yrsgeen gegevensgeen gegevens
Raymond Sweet
Member of Scientific Advisory Board7.9yrsgeen gegevensgeen gegevens
Sharon Curran
Independent Member of Supervisory Board5.2yrs€92.60kgeen gegevens
Heinrich V. Moisa
Chairman of the Supervisory Boardless than a yeargeen gegevensgeen gegevens
Silke Mainka
Member of the Supervisory Boardless than a yeargeen gegevensgeen gegevens
Romain Lege
Deputy Chairman of the Supervisory Boardless than a yeargeen gegevensgeen gegevens

6.5yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: MOR's board of directors are considered experienced (6.5 years average tenure).